Swiss Public Assessment Report (SwissPAR)

Following the entry into force of the revised Therapeutic Products Act, Swissmedic publishes additional information of general interest relating to therapeutic products. On the basis of Art. 67 para. 1 TPA and the implementing provisions of Art. 68 para. 1 let. e TPO, the Agency publishes a SwissPAR summary evaluation report for all human medicinal products with a new active substance, as well as for transplant products, for which a decision to approve or reject authorisation has been issued. It also publishes a supplementary report for approved or rejected applications relating to additional indications for human medicinal products for which a SwissPAR has been published following the new authorisation. The SwissPAR includes the evaluation results of the application for new authorisation or additional indication of a human medicinal product, but not the applicant's commercial or manufacturing secrets or personal data.

The SwissPAR is intended primarily for healthcare professionals, industry representatives and other national and international authorities. Swissmedic publishes the SwissPAR in English using specific technical terminology.

In addition to the full SwissPAR, Swissmedic is publishing an abridged version of the SwissPAR known as the ‘Public Summary SwissPAR’. The Public Summary SwissPAR is intended to make Swissmedic's authorisation decisions comprehensible and transparent to the wider public, and to give them access to relevant information on medicinal products.


Sorted by name of the medicinal product

A - C

SwissPAR – Beovu (PDF, 833 kB, 03.08.2022)Extension of therapeutic indication (01)

SwissPAR – Brukinsa (PDF, 896 kB, 03.11.2023)Extension of therapeutic indication (01)

SwissPAR – Cablivi (PDF, 903 kB, 03.09.2021)Extension of therapeutic indication (01)

L - N

SwissPAR – Nubeqa (PDF, 408 kB, 30.03.2023)Extension of therapeutic indication (01)

SwissPAR – Nuvaxovid (PDF, 459 kB, 05.01.2023)Extension of therapeutic indication (01)

O - R

SwissPAR – Rinvoq (PDF, 760 kB, 31.05.2021)Extension of therapeutic indication (01)

SwissPAR – Rinvoq (PDF, 781 kB, 31.05.2021)Extension of therapeutic indication (02)

SwissPAR – Rinvoq (PDF, 1 MB, 20.01.2022)Extension of therapeutic indication (03)

S - U

SwissPAR – Sarclisa (PDF, 779 kB, 06.09.2023)Extension of therapeutic indication (01)

SwissPAR – Spravato (PDF, 1017 kB, 20.10.2021)Extension of therapeutic indication (01)

SwissPAR – Trikafta (PDF, 849 kB, 18.11.2021)Extension of therapeutic indication (01)

SwissPAR – Trikafta (PDF, 649 kB, 30.03.2022)Extension of therapeutic indication (02)

SwissPAR – Trodelvy (PDF, 797 kB, 09.10.2023)Extension of therapeutic indication (01)

SwissPAR – Ultomiris (PDF, 624 kB, 16.09.2021)Extension of therapeutic indication (01)

SwissPAR – Ultomiris (PDF, 573 kB, 22.08.2022)Extension of therapeutic indication (02)

Last modification 13.11.2023

Top of page